Showing 5261-5270 of 7518 results for "".
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Analysis: Scar Reduction Seen with Fractional CO2 and 5-FU Laser Treatmentshttps://practicaldermatology.com/news/analysis-scar-reduction-seen-fractional-co2-and-5-fu-laser-treatments/2463110/Results from a new meta-analysis suggest that fractional carbon dioxide (FCO2) plus 5-fluorouracil (5-FU) laser therapy was effective in treating hypertrophic and keloid scars. Researchers for the analysis included data from 18 studies (N = 550). The team comprehensively search
- Survey Shows Variability in Hyaluronidase Use Among Practitionershttps://practicaldermatology.com/news/survey-shows-variability-hyaluronidase-use-among-practitioners/2463109/New research suggests there are inconsistencies in the use of hyaluronidase (HYAL) for the treatment of adverse events with hyaluronic acid (HA) fillers, suggesting a need for standardized guidelines. "With the growing popularity and administration of HA fillers, there is likely to be a c
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support
- LEO Pharma Announces Topline Results of Phase 3 Trial in China for Plaque Psoriasis Treatment Enstilarhttps://practicaldermatology.com/news/leo-pharma-announces-topline-results-phase-3-trial-china-plaque-psoriasis-treatment-enstilar/2463007/LEO Pharma announced results from the Enstilar phase 3 trial in China in adult patients living with stable plaque psoriasis. The trial is a phase 3, randomised, investigator-blind, active controlled, parallel group, multicenter trial comparing the efficacy and safety of once daily Enstila
- Meta-Analysis: Avelumab Offers Hope for Advanced MCC Patientshttps://practicaldermatology.com/news/meta-analysis-avelumab-offers-hope-for-advanced-mcc-patients/2463006/A recent meta-analysis indicated that avelumab monotherapy and combination therapy shown improvement in overall response and survival rates in patients with advanced Merkel cell carcinomas (MCC). The study, published in Dermatologic Surgery, surveyed results from 48 studies invol
- Fish Residues Could Supply Collagenhttps://practicaldermatology.com/news/fish-residues-could-supply-collagen/2462980/Researchers in Norway believe fish residues can supplement current sources of raw materials for collagen and gelatin, according to a Phys.org article. A project called SUPREME, headed by the Norwegian science institute SINTEF Ocean in collaboration with Norwegian university NTNU and the T
- Study: Markers Reveal New Diagnostic Paths in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/study-markers-reveal-new-diagnostic-paths-chronic-spontaneous-urticaria/2462978/A recent study highlighted new diagnostic markers and pathways in chronic spontaneous urticaria (CSU). Researchers publishing in the International Journal of Dermatology included 90 CSU patients and 90 healthy individuals in the analysis. The authors then analyzed markers from di